{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:29:56Z","timestamp":1786969796651,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114175","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:26:35Z","timestamp":1718310395000},"page":"114175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of cyclin dependent kinase 4\/6 inhibitors on breast cancer brain metastasis outcomes"],"prefix":"10.1016","volume":"207","author":[{"given":"Sonya M.","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Safonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114175_bib1","unstructured":"Female Breast Cancer Subtypes - Cancer Stat Facts. 2023 Dec 12, https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"issue":"9","key":"10.1016\/j.ejca.2024.114175_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114175_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clbc.2021.01.017","article-title":"Epidemiology of de novo metastatic breast cancer","volume":"21","author":"Daily","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114175_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol, Biomark Prev"},{"issue":"6","key":"10.1016\/j.ejca.2024.114175_bib5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2020","journal-title":"Neuro-Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2024.114175_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2024.114175_bib7","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"59","key":"10.1016\/j.ejca.2024.114175_bib8","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.18632\/oncotarget.27238","article-title":"Central nervous system-specific efficacy of CDK4\/6 inhibitors in randomized controlled trials for metastatic breast cancer","volume":"10","author":"Nguyen","year":"2019","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejca.2024.114175_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000504405","article-title":"Ribociclib in breast cancer brain metastases: a case report","volume":"15","author":"Radke","year":"2020","journal-title":"Breast Care"},{"issue":"20","key":"10.1016\/j.ejca.2024.114175_bib10","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.114175_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-013-1083-9","article-title":"The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer","volume":"112","author":"Sperduto","year":"2013","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114175_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","article-title":"Beyond an updated graded prognostic assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today","volume":"107","author":"Sperduto","year":"2020","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"6","key":"10.1016\/j.ejca.2024.114175_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.seminoncol.2018.01.006","article-title":"Mechanisms of therapeutic CDK4\/6 inhibition in breast cancer","volume":"44","author":"Scott","year":"2017","journal-title":"Semin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2024.114175_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ejca.2024.114175_bib15","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2024.114175_bib16","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2024.114175_bib17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of cdk4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114175_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114175_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","article-title":"Leptomeningeal carcinomatosis in patients with breast cancer","volume":"135","author":"Franzoi","year":"2019","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ejca.2024.114175_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.breast.2020.11.019","article-title":"Complete response of leptomeningeal carcinomatosis secondary to breast cancer","volume":"54","author":"Troussier","year":"2020","journal-title":"Breast (Edinb, Scotl)"},{"issue":"1","key":"10.1016\/j.ejca.2024.114175_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","article-title":"Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype","volume":"136","author":"Arvold","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ejca.2024.114175_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"issue":"17_suppl","key":"10.1016\/j.ejca.2024.114175_bib23","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","volume":"40","author":"Kalinsky","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114175_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.21037\/tcr-22-2807","article-title":"A narrative review about CDK4\/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer","volume":"12","author":"Zhao","year":"2023","journal-title":"Transl Cancer Res"},{"issue":"28","key":"10.1016\/j.ejca.2024.114175_bib25","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejca.2024.114175_bib26","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.114175_bib27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol: J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114175_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.18632\/oncotarget.2673","article-title":"Cyclin E1 and RTK\/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS","volume":"6","author":"Taylor-Harding","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.ejca.2024.114175_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2024.114175_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.19.00090","article-title":"Cyclin E mRNA: assessing cyclin-dependent kinase (CDK) activation state to elucidate breast cancer resistance to CDK4\/6 inhibitors","volume":"37","author":"Chandarlapaty","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114175_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ejca.2024.114175_bib32","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.114175_bib33","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejca.2024.114175_bib34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ejca.2024.114175_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ejca.2024.114175_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ejca.2024.114175_bib37","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:10Z","timestamp":1786969330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"alternative-id":["S0959804924008311"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114175","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of cyclin dependent kinase 4\/6 inhibitors on breast cancer brain metastasis outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114175"}}